Cell type-specific anti-cancer properties of valproic acid: Independent effects on HDAC activity and Erk1/2 phosphorylation

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gotfryd, Kamil ^a   Skladchikova, Galina ^a   Lepekhin, Eugene A ^a   Berezin, Vladimir ^a   Bock, Elisabeth ^a   Walmod, Peter S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; RAS PROTEIN; VALPROIC ACID; ENZYME INHIBITOR;

ACETYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL MOTILITY; CELL TYPE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; WESTERN BLOTTING;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RATS; VALPROIC ACID;

EID: 77954682038     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-383     Document Type: Article

References (43)

1. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003, 9:199-216.
2. Kostrouchova M, Kostrouch Z, Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biologica (Praha) 2007, 53:37-49.
3. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954. 10.1002/cncr.22891, 17647267.
4. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treatment Reviews 2008, 34:206-222. 10.1016/j.ctrv.2007.11.003, 18226465.
5. Michaelis M, Doerr HW, Cinatl J. Valproic acid as anti-cancer drug. Current Pharmaceutical Design 2007, 13:3378-3393. 10.2174/138161207782360519, 18045192.
6. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 2001, 276:36734-36741. 10.1074/jbc.M101287200, 11473107.
7. Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002, 22:492-511. 10.1002/med.10017, 12210556.
8. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. Journal of Cell Science 2004, 117:4619-4628. 10.1242/jcs.01481, 15371522.
9. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239. 10.1038/sj.onc.1210414, 17496918.
10. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44. 10.1080/02699050500284218, 16393692.
11. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121. 10.1038/sj.onc.1210394, 17496910.
12. Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene 1998, 17:1447-1455. 10.1038/sj.onc.1202251, 9779990.
13. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Experimental Cell Research 1999, 253:34-46. 10.1006/excr.1999.4689, 10579909.
14. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 2007, 213:589-602. 10.1002/jcp.21246, 17786953.
15. Knupfer MM, Pulzer F, Schindler I, Hernaiz Driever P, Knupfer H, Keller E. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001, 21:347-351.
16. Witt O, Monkemeyer S, Kanbach K, Pekrun A. Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. American Journal of Hematology 2002, 71:45-46. 10.1002/ajh.10161, 12221674.
17. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. Journal of Biological Chemistry 2001, 276:31674-31683. 10.1074/jbc.M104309200, 11418608.
18. Gotfryd K, Owczarek S, Hoffmann K, Klementiev B, Nau H, Berezin V, Bock E, Walmod PS. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007, 52:764-778. 10.1016/j.neuropharm.2006.09.017, 17095022.
19. Walmod PS, Hartmann-Petersen R, Berezin A, Prag S, Kiselyov VV, Berezin V, Bock E. Evaluation of individual-cell motility. Methods in Molecular Biology 2001, 161:59-83.
20. Pullikuth AK, Catling AD. Scaffold mediated regulation of MAPK signaling and cytoskeletal dynamics: a perspective. Cell Signal 2007, 19:1621-1632. 10.1016/j.cellsig.2007.04.012, 2233890, 17553668.
21. Walmod PS, Foley A, Berezin A, Ellerbeck U, Nau H, Bock E, Berezin V. Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues. Cell Motilility and the Cytoskeleton 1998, 40:220-237.
22. Yamamoto T, Taya S, Kaibuchi K. Ras-Induced Transformation and Signaling Pathway. J Biochem 1999, 126:799-803.
23. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 2001, 20:6969-6978. 10.1093/emboj/20.24.6969, 125788, 11742974.
24. Blaheta RA, Nau H, Michaelis M, Cinatl J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002, 9:1417-1433.
25. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005, 114:380-386. 10.1002/ijc.20774, 15578701.
26. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006, 66:7237-7244. 10.1158/0008-5472.CAN-05-0487, 16849572.
27. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004, 24:6590-6599. 10.1523/JNEUROSCI.5747-03.2004, 15269271.
28. Di Daniel E, Mudge AW, Maycox PR. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord 2005, 7:33-41. 10.1111/j.1399-5618.2004.00164.x, 15654930.
29. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel D, Zornig M, Nau H, Fleming I, Doerr HW, Cinatl J. Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ 2006, 13:446-453. 10.1038/sj.cdd.4401759, 16167071.
30. Vulcano F, Ciccarelli C, Mattia G, Marampon F, Giampiero M, Milazzo L, Pascuccio M, Zani BM, Giampaolo A, Hassan HJ. HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers. Experimental Cell Research 2006, 312:1590-1597. 10.1016/j.yexcr.2006.01.017, 16739251.
31. Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, Hwang JW, Jung JY, Kim SH, Kang KS, Lee YS. Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer Lett 2005, 225:199-206. 10.1016/j.canlet.2004.11.029, 15978324.
32. Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, Dent P, Grant S. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003, 2:544-551.
33. Michaelis M, Suhan T, Reinisch A, Reisenauer A, Fleckenstein C, Eikel D, Gumbel H, Doerr HW, Nau H, Cinatl J. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest Ophthalmol Vis Sci 2005, 46:3451-3457. 10.1167/iovs.05-0369, 16123451.
34. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007, 14:839-845. 10.1677/ERC-07-0096, 17914112.
35. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004, 64:1079-1086. 10.1158/0008-5472.CAN-03-0799, 14871841.
36. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007, 27:197-213. 10.1016/j.molcel.2007.05.033, 2684874, 17643370.
37. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 2008, 60:261-310. 10.1124/pr.107.00106, 18922965.
38. Fuller LC, Cornelius SK, Murphy CW, Wiens DJ. Neural crest cell motility in valproic acid. Reproductive Toxicology 2002, 16:825-839. 10.1016/S0890-6238(02)00059-X, 12401512.
39. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 2006, 319:533-542. 10.1124/jpet.106.106658, 16868035.
40. De Girolamo LA, Billett EE. Role of extracellular-regulated kinase and c-Jun NH2-terminal kinase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurofilament phosphorylation. J Neurosci Res 2006, 83:680-693. 10.1002/jnr.20765, 16447269.
41. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004, 90:283-288. 10.1038/sj.bjc.6601488, 2409554, 14735164.
42. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23:6771-6790. 10.1200/JCO.2005.08.036, 16170185.
43. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007, 85:159-170. 10.1007/s11060-007-9402-7, 17534580.